1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends

Vital Signs - Healthcare News - The Analyst's Perspective - May Issue

  • June 2014
  • 8 pages
  • Frost & Sullivan
Report ID: 2154567


Table of Contents

This issue of Vital Signs, released on June 2, 2014, discusses the latest strategy surrounding mega deals in the pharma/biotech industry, Eurofins agreement to acquire ViroCor-IBT Laboratories, Qiagen's acquisition of BIOBASE, and the FDA's latest announcement on regulatory requirements for biosimilars.


FDA breaks silence on biosimilars with long-awaited proposal

Source: FierceBiotech, May 14, 2014

In a non-binding draft guidance, the agency spelled out four tiers of possible similarity between an under-review treatment and the approved biologic it hopes to replace. In the best-case scenario, biosimilar developers would need only targeted animal or human studies to prove their drugs match their references, while those deemed not similar would no longer be considered without changes to their manufacturing processes. The FDA’s latest announcement explains how the agency will require drugmakers to submit analytical data comparing biosimilar candidates to their forebears. Depending on what differences those analyses find, the FDA will file each submitted treatment into one of four categories:

- Highly similar with fingerprint-like similarity, in which a submission is deemed nearly identical to its reference product, “based on integrated, multi-parameter approaches,” according to the FDA. Such drugs would need only “targeted and selective” further study to demonstrate their biosimilarity.
- Highly similar, which also meets the statutory standard for similarity but falls short of the above-mentioned gold standard.
- Similar, a label that applies to drugs whose analyses were inconclusive, demanding further data or studies to figure out whether changes in manufacturing or formulation might help demonstrate similarity.
- Not similar, the draft’s most self-explanatory tier, applies to products that don’t measure up to their references.
The Analyst’s Perspective by Steven Atkinson, Senior Industry Analyst,
Life Sciences, North America

It has been four years since Congress authorized the agency to define an appropriate approval pathway for biologic copies in hopes to reduce the biologics healthcare cost. With 40 biosimilar programs in Phase 3 trials, the FDA was forced to deliver some type of clarity. Ongoing clinical research on potential pipeline products; patent expirations of various matured biologics such as Neupogen, Humira, and Lantus; and the increasing demand for the first-wave biosimilar products such as somatropin, filgrastim, and erythropoietin, will help lower the biological product prices. The FDA had to act, but as usual, it is not at lightning speed. These four segmentations are out for public discussion until August 12, 2014, and then it is back to the committee. Meanwhile, the US multibillion-dollar market for biosimilars remains on hold as the FDA discusses its rules. The eventual approval of biosimilars will hopefully decrease the biologics by at least half, similar to how generic affects the pharmaceuticals. The European Medicines Agency has already authorized the approval of 18 biosimilar drugs. The FDA is one of the last agencies to finalize guidance on biosimilars.

Regulatory guidelines for biosimilars have been adopted in over 60 countries to date, but global harmonization of requirements for approval remains a future ideal, rather than a reality. “Biosimilar manufacturers face many challenges, such as upfront manufacturing costs, demonstrating biosimilarity, designing clinical trials to meet ever-changing regulations, assuaging physician concerns about comparability to the original brand, and product differentiation. We are still a long way from global harmonization, so it is critical to understand the regional differences within the competitive and regulatory landscape,” said a senior executive of a pharmaceutical manufacturer.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Amrita helps you find the right report:


The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

OpportunityAnalyzer: Growth Hormone Deficiency - Opportunity Analysis and Forecasts to 2026

  • $ 10995
  • Industry report
  • May 2017
  • by GlobalData

OpportunityAnalyzer: Growth Hormone Deficiency - Opportunity Analysis and Forecasts to 2026 Summary Growth hormone deficiency (GHD) is a rare endocrine disorder characterized by inadequate secretion of ...

Erythropoietin (EPO) Drugs Market Analysis By Drug Class (Biologics, Biosimilars), By Product (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others), By Application, And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • May 2017
  • by Grand View Research

The global erythropoietin (EPO) drugs market is expected to reach USD 17.4 billion by 2025, according to a new report by Grand View Research, Inc. Rising incidence of chronic diseases such as CKD and cance ...

Global Biosimilars Market

  • $ 4250
  • Industry report
  • July 2017
  • by Mordor Intelligence LLP

The global biosimilar market was estimated to be USD XX million in 2016 and is expected to reach USD XX million by 2021, witnessing a CAGR of XX% during the forecast period. Biosimilar is a biological ...


Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.